Product image of Medikinet Cr (Methylphenidate Hydrochloride) supplied by GNH India

Medikinet Cr

Active Ingredient:
Methylphenidate Hydrochloride
Origin:
EU

Medikinet Cr (Methylphenidate Hydrochloride)

Methylphenidate Hydrochloride, the active ingredient in Medikinet Cr, is a central nervous system stimulant presented as an extended‑release tablet for oral use. It is indicated for the management of attention deficit hyperactivity disorder and narcolepsy, helping improve concentration, impulse control, and wakefulness in children, adolescents, and adults.

GNH India supplies Medikinet Cr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory requirements across all markets.

Manufacturer / TM Owner

Medice Arzneimittel Pütter Gmbh & Co. Kg

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Medikinet Cr is a central nervous system stimulant used in the treatment of neurodevelopmental and sleep‑wake disorders.

  • Attention deficit hyperactivity disorder (ADHD): improves attention, reduces hyperactivity and impulsivity.
  • Narcolepsy: decreases excessive daytime sleepiness and cataplexy episodes.
  • Adult ADHD: enhances focus and productivity in adult patients.

How It Works

  • Methylphenidate hydrochloride blocks the reuptake transporters for dopamine and norepinephrine in neuronal synapses, raising extracellular concentrations of these catecholamines. The increased neurotransmitter activity, particularly in the prefrontal cortex, enhances neuronal signaling that underlies attention, executive function, and wakefulness.

Side Effects

Common Side Effects

  • Insomnia: difficulty falling or staying asleep.
  • Decreased appetite: reduced desire for food, especially in children.
  • Headache: mild to moderate head pain.
  • Stomach pain: abdominal discomfort or nausea.
  • Weight loss: unintended reduction in body weight.
  • Irritability: increased mood swings or agitation.

Serious or Rare Side Effects

  • Cardiovascular events: hypertension, tachycardia, or arrhythmias.
  • Psychosis: new or worsening hallucinations or delusional thoughts.
  • Severe allergic reactions: rash, swelling, or anaphylaxis.
  • Priapism: prolonged painful erection.
  • Seizures: convulsive episodes in susceptible individuals.
  • Mood disorders: severe depression or suicidal thoughts.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient history and monitor ongoing safety.

  • Cardiovascular assessment: review history of heart disease, hypertension, or arrhythmias.
  • Psychiatric monitoring: observe for new or worsening psychiatric symptoms.
  • Growth monitoring: regularly track height and weight in pediatric patients.
  • Abuse potential: prescribe only when benefits outweigh risk of misuse.
  • Drug interaction review: assess concomitant medications for possible interactions.
  • Store at ambient temperature: keep tablets below 25 °C in original packaging, protected from moisture.

Avoid Interactions

Methylphenidate may interact with several drug classes; careful review is required.

Major Interactions (Avoid)

  • Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis.
  • Tricyclic antidepressants: increased cardiovascular side effects.
  • Antihypertensive agents: may reduce blood‑pressure‑lowering efficacy.

Moderate Interactions (Monitor Closely)

  • Proton pump inhibitors: possible alteration of drug absorption.
  • Anticonvulsants (e.g., carbamazepine): may affect plasma concentrations.
  • Alcohol: can enhance central nervous system stimulation.

Frequently Asked Questions

Medikinet Cr is a prescription medication containing methylphenidate hydrochloride. It is approved for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy, helping to improve focus, reduce hyperactivity, and lessen excessive daytime sleepiness in patients of various ages.

Methylphenidate blocks the reuptake of dopamine and norepinephrine at neuronal synapses, increasing their concentrations in the brain. The heightened neurotransmitter activity, especially in the prefrontal cortex, enhances pathways that regulate attention, impulse control, and wakefulness.

The dose of Medikinet Cr is individualized. A qualified prescriber determines the appropriate strength and dosing schedule based on the patient’s age, weight, clinical response, and tolerability. No fixed regimen is provided here.

Safety data for methylphenidate during pregnancy and lactation are limited. It is generally prescribed only when the potential benefit outweighs the risk to the fetus or infant. Physicians should carefully assess each case and discuss possible risks with the patient.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Medikinet Cr provides extended‑release delivery, offering smoother plasma levels and once‑daily dosing compared with immediate‑release methylphenidate. Compared with amphetamine‑based stimulants, it has a distinct pharmacologic profile and may present different side‑effect patterns, allowing clinicians to tailor therapy to individual patient needs.

Store the tablets at ambient temperature below 25 °C in the original blister pack or container, protected from moisture and direct sunlight. Keep the medication out of reach of children and do not use it after the printed expiry date.

Medikinet Cr tablets are taken orally, usually with or without food, as directed by the prescriber. The tablet should be swallowed whole; it must not be split, chewed, or crushed, as this would disrupt the extended‑release mechanism.

Serious adverse events include cardiovascular complications such as hypertension or tachycardia, new or worsening psychiatric symptoms like psychosis, and rare allergic reactions. Patients should seek immediate medical attention for chest pain, severe mood changes, or signs of an allergic response.

Individuals with known hypersensitivity to methylphenidate, severe cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, or a history of substance abuse should avoid Medikinet Cr. It is also contraindicated in patients currently taking monoamine oxidase inhibitors.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Methylphenidate Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT